Participants 85 133 3
very platinum-sensitive ovarian cancer patients:
Participants 222 342 5
analysis of patients with very platinum-sensitive recurrent ovarian cancer (ROC) enrolled in the phase III CALYPSO trial
Participants 365 526 5
The international non-inferiority trial enrolled women with ROC that relapsed >6 months following first- or second-line platinum- and paclitaxel-based therapies.
Participants 875 959 3
A total of 259 very platinum-sensitive patients were included (n=131, CD; n=128, CP)
Participants 1819 1861 3
patients with very platinum-sensitive ROC.
